Goldman Sachs Reaffirms Their Buy Rating on Tenet Healthcare (THC)

In a report released yesterday, Scott Fidel from Goldman Sachs maintained a Buy rating on Tenet Healthcare, with a price target of $252.00.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Fidel covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Centene, and Elevance Health. According to TipRanks, Fidel has an average return of 8.3% and a 64.37% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenet Healthcare with a $255.40 average price target.

Based on Tenet Healthcare’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.37 billion and a net profit of $702 million. In comparison, last year the company earned a revenue of $5.22 billion and had a net profit of $406 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in March 2026, Paola M Arbour, the EVP & CIO of THC sold 6,500.00 shares for a total of $1,549,795.00.